EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 363 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Life-saving scheme to improve cancer screening among Muslim women July 20, 2023 Happy New Year From Our Team January 4, 2021 Toddler Celebrates 11 Months Cancer-Free In Adorable Dance Video With Dad. October 17, 2019 FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma April 29, 2021 Load more HOT NEWS Reflections N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by... ASCO20 Virtual Research Round Up Podcast: Head and Neck Cancer and... ΝΕΥΡΟΕΝΔΟΚΡΙΝΕΙΣ ΟΓΚΟΙ (ΝΕΤS)
